| | Characteristics | Results |
| | Sex | | | Men | 272 (26.8%) | | Women | 743 (73.2%) | | Age (mean ± SD, years) | 43.4 ± 12.2 | | ≥55 | 195 (19.2%) | | <55 | 820 (80.8%) | | BMI (Mean ± SD, kg/m2) | 24.03 ± 3.88 | | Normal | 647 (63.7%) | | Overweight | 310 (30.5%) | | Obesity | 58 (5.7%) | | BFP (Mean ± SD,%) | 24.30 ± 10.49 | | Nonobesity (men) | 111 (10.9%) | | Obesity (men) | 161 (15.9%) | | Nonobesity (women) | 481 (47.4%) | | Obesity (women) | 262 (25.8%) | | BSA (mean ± SD, m2) | 1.70 ± 0.18 | | Nonobesity (men) | 62 (6.1%) | | Obesity (men) | 210 (20.7%) | | Nonobesity (women) | 586 (57.7%) | | Obesity (women) | 157 (15.5%) | | Maximum tumor size (Mean ± SD, cm) | 1.32 ± 1.00 | | ≤1 | 531 (52.3%) | | >1 to ≤2 | 325 (32.0%) | | >2 to ≤4 | 134 (13.2%) | | >4 | 25 (2.5%) | | The number of foci | | | 1 | 679 (66.9%) | | 2 | 223 (22.0%) | | 3 or more | 113 (11.1%) | | BRAF V600E mutation | 839 (82.7%) | | CLT | 272 (26.8%) | | ETE | 207 (20.4%) | | CLNM | 593 (58.4%) | | LLNM | 211 (20.8%) | | Level II metastasis | 94 (9.3%) | | Level III metastasis | 160 (15.8%) | | Level IV metastasis | 176 (17.3%) | | Level V metastasis | 48 (4.7%) | | Skip metastasis | 22 (2.2%) | | MLLNM | 181 (17.8%) | | Simultaneous metastasis in LC | 162 (16.0%) | | No. of removed LNs in CC (mean ± SD) | 7.6 ± 5.0 | | No. of metastatic LNs in CC (mean ± SD) | 2.1 ± 2.9 | | Central LNR (mean ± SD) | 0.29 ± 0.33 | | No. of removed LNs in LC (mean ± SD) | 28.0 ± 10.9 | | No. of metastatic LNs in LC (mean ± SD) | 5.3 ± 4.0 | | Lateral LNR (mean ± SD) | 0.05 ± 0.31 |
|
|
PTC, papillary thyroid carcinoma; SD, standard deviation; BMI, body mass index; BFP, body fat percentage; BSA, body surface area; CLT, chronic lymphocytic thyroiditis; ETE, extrathyroidal extension; CLNM, central lymph node metastasis; LLNM, lateral lymph node metastasis; MLLNM, multiple lateral lymph node metastasis; LN, lymph node; CC, central compartment; LC, lateral compartment; and LNR, lymph node ratio.
|
